Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ATHE 
Alterity Therapeutics Ltd (ATHE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ATHE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $11
1 Year Target Price $11
| 1 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -51.42% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 75.00M USD | Price to earnings Ratio - | 1Y Target Price 11 |
Price to earnings Ratio - | 1Y Target Price 11 | ||
Volume (30-day avg) 3 | Beta 0.51 | 52 Weeks Range 1.00 - 7.00 | Updated Date 08/28/2025 |
52 Weeks Range 1.00 - 7.00 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.23 |
Earnings Date
Report Date 2025-08-04 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -469.68% |
Management Effectiveness
Return on Assets (TTM) -78.37% | Return on Equity (TTM) -155.77% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 66350782 | Price to Sales(TTM) 20.14 |
Enterprise Value 66350782 | Price to Sales(TTM) 20.14 | ||
Enterprise Value to Revenue 113.99 | Enterprise Value to EBITDA 0.75 | Shares Outstanding 14803400 | Shares Floating 4319368081 |
Shares Outstanding 14803400 | Shares Floating 4319368081 | ||
Percent Insiders - | Percent Institutions 1.45 |
Upturn AI SWOT
Alterity Therapeutics Ltd
Company Overview
History and Background
Alterity Therapeutics Ltd (formerly Prana Biotechnology) was founded in 1997. It focuses on developing treatments for neurodegenerative diseases. Initial research centered on PBT2 for Alzheimer's and Huntington's disease. It has evolved to focus on iron dysregulation in neurological disorders.
Core Business Areas
- Drug Development: Developing drugs to treat neurodegenerative diseases, specifically focusing on iron dysregulation.
- Clinical Trials: Conducting clinical trials to test the efficacy and safety of their drug candidates.
Leadership and Structure
Dr. David Stamler is the current CEO. The company has a board of directors overseeing strategy and operations. The organizational structure includes research, clinical development, and administrative departments.
Top Products and Market Share
Key Offerings
- ATH434: ATH434 (formerly PBT434) is Alterity's lead drug candidate, being developed for the treatment of Multiple System Atrophy (MSA) and other synucleinopathies. There is no current market share as the drug is still in clinical development. Competitors include companies developing therapies targeting alpha-synuclein aggregation. Key competitors include Biogen (BIIB) and UCB S.A. (UCBJF).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive with significant investment in R&D. The market for neurodegenerative disease treatments is large and growing due to aging populations.
Positioning
Alterity is a smaller biotechnology company focused on a niche within the neurodegenerative disease space u2013 iron dysregulation. Their competitive advantage lies in their specific targeting of this pathway.
Total Addressable Market (TAM)
The TAM for neurodegenerative diseases is estimated to be in the tens of billions of dollars. Alterity is positioned to capture a portion of this market if ATH434 proves successful. The exact market size depends on the specific indications targeted, such as MSA, which is estimated to be several billion dollars.
Upturn SWOT Analysis
Strengths
- Novel therapeutic target (iron dysregulation)
- Experienced management team
- Promising preclinical and clinical data for ATH434
- Orphan drug designation for ATH434 in MSA
Weaknesses
- Limited financial resources
- High risk associated with drug development
- Dependence on a single lead product candidate
- Small market capitalization
Opportunities
- Positive clinical trial results for ATH434
- Partnerships with larger pharmaceutical companies
- Expansion into other neurodegenerative diseases
- Government grants and funding
Threats
- Clinical trial failures
- Competition from larger pharmaceutical companies
- Regulatory hurdles
- Patent expirations
Competitors and Market Share
Key Competitors
- BIIB
- UCBJF
- TEVA
- SNY
- ABBV
Competitive Landscape
Alterity is a smaller player compared to larger pharmaceutical companies. Its competitive advantage lies in its novel therapeutic target and focus on iron dysregulation.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by advancing clinical trials and securing funding. There is no revenue to speak of.
Future Projections: Future growth depends on the successful development and commercialization of ATH434. Analyst estimates vary widely based on the probability of success.
Recent Initiatives: Recent initiatives include advancing the Phase 2 clinical trial of ATH434 in MSA and exploring potential partnerships.
Summary
Alterity Therapeutics is a high-risk, high-reward clinical-stage company focused on a novel therapeutic target in neurodegenerative diseases. Its success hinges on the clinical development of ATH434. Positive clinical trial results and securing funding or partnerships are critical for its future. The company needs to be very cautious of competitors and of spending too much.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
- Third Party Finanical reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data is based on available public information and may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alterity Therapeutics Ltd
Exchange NASDAQ | Headquaters Melbourne, VIC, Australia | ||
IPO Launch date 2002-09-05 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 10 | Website https://alteritytherapeutics.com |
Full time employees 10 | Website https://alteritytherapeutics.com | ||
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.